SEREVENT DISKUS Rx
Generic Name and Formulations:
Salmeterol (as xinafoate) 50mcg/inh; dry pwd for inhalation; device with drug in blisters.
Indications for SEREVENT DISKUS:
As an adjunct (see full labeling): For the maintenance treatment of asthma and in the prevention of bronchospasm in reversible obstructive airway disease (including nocturnal asthma). Maintenance treatment of COPD-associated bronchospasm. Prevention of exercise-induced bronchospasm (EIB).
Adults and Children:
<4yrs: not recommended. ≥4yrs: 1 inh every 12 hours. EIB prevention: 1 inh at least 30 minutes before exercise. Max 2 doses/day. Do not use additional doses for EIB if already using regular dosing for asthma. COPD-associated bronchospasm: 1 inh every 12 hours.
For asthma: without concomitant use of a long-term asthma control drug (eg, inhaled corticosteroid). Primary treatment of status asthmaticus or acute episodes of asthma or COPD requiring intensive measures. Allergy to milk proteins.
Increased risk of asthma-related deaths and hospitalizations. Prescribe for asthma only as additional therapy with an inhaled corticosteroid. Do not initiate in rapidly or acutely deteriorating asthma or COPD. Not for relief of acute bronchospasm. Salmeterol is not a substitute for steroids. Not for use with other long-acting β2-agonists. Do not exceed recommended dose. Cardiovascular disease (esp. coronary insufficiency, arrhythmias, hypertension). Convulsive disorders. Thyrotoxicosis. Hyperresponsiveness to sympathomimetics. Diabetes. Ketoacidosis. Hypokalemia. Hyperglycemia. Hepatic impairment (monitor). Evaluate response before altering steroid doses. Prescribe an additional short-acting, inhaled β2-agonist for acute symptoms; monitor for increased need. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Long-acting beta-2 agonist (LABA).
Concomitant strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir, atazanavir, clarithromycin, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin): not recommended. Caution during or within 2 weeks of MAOIs or tricyclic antidepressants (increased cardiovascular effects). Antagonized by β-blockers. Caution with K+-depleting diuretics.
Headache, influenza, nasal/sinus congestion, pharyngitis, rhinitis, tracheitis/bronchitis, cough, musculoskeletal pain, throat irritation, viral respiratory infection; paradoxical bronchospasm (discontinue if occurs); rarely: serious asthma episode, asthma-related death.
Diskus (w. 60 blisters)—1
Clinical Pain Advisor Articles
- Analyzing Coverage of Nonpharmacologic Treatments for Low Back Pain
- Smartphone App Helps Evaluate Catastrophizing in Chronic Pain
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Dsuvia Gains FDA Approval: We Want to Hear Your Thoughts
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Dozens of Medical Groups Join Forces to Improve Diagnoses
- FDA Grants Non-Opioid Analgesic VVZ-149 Fast Track Status
- Little to No Association Found Between Physician Performance and Medical School Ranking